{"id":56405,"date":"2026-02-05T20:26:48","date_gmt":"2026-02-05T12:26:48","guid":{"rendered":"https:\/\/flcube.com\/?p=56405"},"modified":"2026-02-05T20:26:49","modified_gmt":"2026-02-05T12:26:49","slug":"takeda-ends-128m-kyoto-university-ipsc-project-after-decade-of-research","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56405","title":{"rendered":"Takeda Ends $128M Kyoto University iPSC Project After Decade of Research"},"content":{"rendered":"\n<p><strong>Takeda Pharmaceutical<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/4502:TYO\">TYO:\u202f4502<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/TAK:NYSE\">NYSE:\u202fTAK<\/a>) announced the termination of its <strong>ten\u2011year induced pluripotent stem cell (iPSC) research project<\/strong> with <strong>Kyoto University<\/strong>, effective at the close of <strong>FY2025<\/strong>. The joint <strong>&#8220;T\u2011CiRA&#8221;<\/strong> program, launched in FY2016 with a total investment of <strong>JPY\u202f20\u202fbillion (USD\u202f128\u202fmillion)<\/strong>, failed to develop any new drugs suitable for real\u2011world clinical application despite generating foundational technology, patents, and academic publications.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-project-status-amp-investment-summary\">Project Status &amp; Investment Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>Takeda Pharmaceutical \/ Kyoto University<\/td><\/tr><tr><td><strong>Project Name<\/strong><\/td><td>T\u2011CiRA (Takeda\u2011CiRA)<\/td><\/tr><tr><td><strong>Launch Date<\/strong><\/td><td>FY2016<\/td><\/tr><tr><td><strong>Termination Date<\/strong><\/td><td>Close of FY2025<\/td><\/tr><tr><td><strong>Total Investment<\/strong><\/td><td>JPY\u202f20\u202fbillion (USD\u202f128\u202fmillion)<\/td><\/tr><tr><td><strong>Outcomes<\/strong><\/td><td>Foundational technology, patents, publications<\/td><\/tr><tr><td><strong>Clinical Success<\/strong><\/td><td>No drugs suitable for real\u2011world application<\/td><\/tr><tr><td><strong>Strategic Rationale<\/strong><\/td><td>Portfolio prioritization away from high\u2011risk, long\u2011term research<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-strategic-implications\">Market Impact &amp; Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>iPSC Market:<\/strong> Global iPSC market valued at <strong>$2.5\u202fbillion<\/strong> : in 2025; pharma\u2011led clinical translation remains challenging<\/li>\n\n\n\n<li><strong>R&amp;D Portfolio:<\/strong> Termination reflects Takeda\u2019s shift toward <strong>near\u2011term, lower\u2011risk pipeline assets<\/strong> following pressure to deliver returns on R&amp;D spending<\/li>\n\n\n\n<li><strong>Financial Impact:<\/strong> $128\u202fM write\u2011off represents <strong>2%<\/strong> of Takeda\u2019s annual R&amp;D budget; frees up resources for oncology and rare disease programs<\/li>\n\n\n\n<li><strong>Academic Partnership:<\/strong> Kyoto University collaboration will continue in other areas; iPSC research may shift to government\u2011funded academic consortia<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> <strong>Fujifilm<\/strong> and <strong>Astellas<\/strong> continue iPSC investments; Takeda\u2019s exit may signal broader industry caution toward stem cell therapies<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Takeda to reallocate JPY\u202f5\u202fbillion annual savings from project termination to <strong>cell therapy manufacturing capabilities<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Takeda\u2019s R&amp;D strategy, portfolio allocation, and market implications of the iPSC project termination. Actual results may differ due to competitive dynamics, regulatory changes, and strategic priorities.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Takeda Pharmaceutical (TYO:\u202f4502, NYSE:\u202fTAK) announced the termination of its ten\u2011year induced pluripotent stem cell (iPSC)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[77,874,345,4585],"class_list":["post-56405","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-cell-therapy","tag-nyse-tak","tag-takeda","tag-tyo-4502-2"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Takeda Ends $128M Kyoto University iPSC Project After Decade of Research - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Takeda Pharmaceutical (TYO:\u202f4502, NYSE:\u202fTAK) announced the termination of its ten\u2011year induced pluripotent stem cell (iPSC) research project with Kyoto University, effective at the close of FY2025. The joint &quot;T\u2011CiRA&quot; program, launched in FY2016 with a total investment of JPY\u202f20\u202fbillion (USD\u202f128\u202fmillion), failed to develop any new drugs suitable for real\u2011world clinical application despite generating foundational technology, patents, and academic publications.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56405\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Takeda Ends $128M Kyoto University iPSC Project After Decade of Research\" \/>\n<meta property=\"og:description\" content=\"Takeda Pharmaceutical (TYO:\u202f4502, NYSE:\u202fTAK) announced the termination of its ten\u2011year induced pluripotent stem cell (iPSC) research project with Kyoto University, effective at the close of FY2025. The joint &quot;T\u2011CiRA&quot; program, launched in FY2016 with a total investment of JPY\u202f20\u202fbillion (USD\u202f128\u202fmillion), failed to develop any new drugs suitable for real\u2011world clinical application despite generating foundational technology, patents, and academic publications.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56405\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-05T12:26:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-05T12:26:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56405#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56405\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Takeda Ends $128M Kyoto University iPSC Project After Decade of Research\",\"datePublished\":\"2026-02-05T12:26:48+00:00\",\"dateModified\":\"2026-02-05T12:26:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56405\"},\"wordCount\":301,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cell-therapy\",\"NYSE: TAK\",\"Takeda\",\"TYO:\u202f4502\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56405#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56405\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56405\",\"name\":\"Takeda Ends $128M Kyoto University iPSC Project After Decade of Research - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-05T12:26:48+00:00\",\"dateModified\":\"2026-02-05T12:26:49+00:00\",\"description\":\"Takeda Pharmaceutical (TYO:\u202f4502, NYSE:\u202fTAK) announced the termination of its ten\u2011year induced pluripotent stem cell (iPSC) research project with Kyoto University, effective at the close of FY2025. The joint \\\"T\u2011CiRA\\\" program, launched in FY2016 with a total investment of JPY\u202f20\u202fbillion (USD\u202f128\u202fmillion), failed to develop any new drugs suitable for real\u2011world clinical application despite generating foundational technology, patents, and academic publications.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56405#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56405\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56405#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Takeda Ends $128M Kyoto University iPSC Project After Decade of Research\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Takeda Ends $128M Kyoto University iPSC Project After Decade of Research - Insight, China&#039;s Pharmaceutical Industry","description":"Takeda Pharmaceutical (TYO:\u202f4502, NYSE:\u202fTAK) announced the termination of its ten\u2011year induced pluripotent stem cell (iPSC) research project with Kyoto University, effective at the close of FY2025. The joint \"T\u2011CiRA\" program, launched in FY2016 with a total investment of JPY\u202f20\u202fbillion (USD\u202f128\u202fmillion), failed to develop any new drugs suitable for real\u2011world clinical application despite generating foundational technology, patents, and academic publications.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56405","og_locale":"en_US","og_type":"article","og_title":"Takeda Ends $128M Kyoto University iPSC Project After Decade of Research","og_description":"Takeda Pharmaceutical (TYO:\u202f4502, NYSE:\u202fTAK) announced the termination of its ten\u2011year induced pluripotent stem cell (iPSC) research project with Kyoto University, effective at the close of FY2025. The joint \"T\u2011CiRA\" program, launched in FY2016 with a total investment of JPY\u202f20\u202fbillion (USD\u202f128\u202fmillion), failed to develop any new drugs suitable for real\u2011world clinical application despite generating foundational technology, patents, and academic publications.","og_url":"https:\/\/flcube.com\/?p=56405","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-05T12:26:48+00:00","article_modified_time":"2026-02-05T12:26:49+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56405#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56405"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Takeda Ends $128M Kyoto University iPSC Project After Decade of Research","datePublished":"2026-02-05T12:26:48+00:00","dateModified":"2026-02-05T12:26:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56405"},"wordCount":301,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cell-therapy","NYSE: TAK","Takeda","TYO:\u202f4502"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56405#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56405","url":"https:\/\/flcube.com\/?p=56405","name":"Takeda Ends $128M Kyoto University iPSC Project After Decade of Research - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-05T12:26:48+00:00","dateModified":"2026-02-05T12:26:49+00:00","description":"Takeda Pharmaceutical (TYO:\u202f4502, NYSE:\u202fTAK) announced the termination of its ten\u2011year induced pluripotent stem cell (iPSC) research project with Kyoto University, effective at the close of FY2025. The joint \"T\u2011CiRA\" program, launched in FY2016 with a total investment of JPY\u202f20\u202fbillion (USD\u202f128\u202fmillion), failed to develop any new drugs suitable for real\u2011world clinical application despite generating foundational technology, patents, and academic publications.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56405#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56405"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56405#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Takeda Ends $128M Kyoto University iPSC Project After Decade of Research"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56405","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56405"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56405\/revisions"}],"predecessor-version":[{"id":56407,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56405\/revisions\/56407"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56405"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56405"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56405"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}